Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | NPC1 | O15118 | 8/20 | 0.49 |
| ▸ | RAB9A | P51151 | 8/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.42 |
| ▸ | RELA | Q04206 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23146389 | 0.83 | CDC7 (0.45) | ALDH1A1KDM4EMAPTHDAC1HDAC6 | |
| SCHEMBL24702521 | 0.82 | ALDH1A1 (0.46) | ALDH1A1KDM4EMAPTNPC1RAB9A | |
| SCHEMBL8564072 | 0.82 | ALDH1A1 (0.44) | ALDH1A1KDM4EMAPTNPC1RAB9A | |
| SCHEMBL7038561 | 0.82 | ALDH1A1 (0.44) | ALDH1A1KDM4EMAPTNPC1RAB9A | |
| SCHEMBL18680563 | 0.82 | CYP2A6 (0.61) | ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1314645 | 0.81 | PTPN11 (0.43) | ALDH1A1KDM4EMAPTNPC1RAB9A | |
| SCHEMBL29065959 | 0.81 | XDH (0.48) | ALDH1A1KDM4EMAPTHDAC1HDAC6 | |
| SCHEMBL16032766 | 0.81 | HDAC1 (0.48) | ALDH1A1KDM4EMAPTNPC1RAB9A | |
| SCHEMBL850770 | 0.81 | SMN1; SMN2 (0.51) | ALDH1A1KDM4EMAPTNPC1RAB9A | |
| SCHEMBL8266782 | 0.81 | CSNK2A1 (0.47) | ALDH1A1KDM4EMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035358-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4620949-A1 | ACKR3 MODULATORS FOR CARDIOVASCULAR OR ANTIPLATELET THERAPY | Eberhard Karls Universität Tübingen (Medizinische Fakultät) (DE) | 2025-09-24 | — | — | EP | disclosed |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-12 | — | — | US | disclosed |
| US-20250171438-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
| CN-116535386-B | Cyanoethylene sulfonyl anilide compound and preparation method and medical application thereof | 西南大学 | 2025-05-27 | — | — | CN | disclosed |
| US-12187720-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-07 | — | — | US | disclosed |
| CN-116535386-A | Cyanoethylene sulfonyl anilide compound and preparation method and medical application thereof | 西南大学 | 2023-08-04 | — | — | CN | disclosed |
| US-20230144755-A1 | PHOTOELECTRIC CONVERSION ELEMENT, IMAGING ELEMENT, OPTICAL SENSOR, AND COMPOUND | FUJIFILM CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20220396586-A1 | THIAZOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2022-12-15 | — | — | US | disclosed |
| US-20220396586-A1 | THIAZOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2022-12-15 | — | — | US | disclosed |
| WO-2004058254-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004041285-A1 | ANTIINFLAMMATION AGENTS | AMGEN INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040097485-A1 | Antiinflammation agents | TULARIK INC. | 2004-05-20 | — | — | US | disclosed |
| EP-0676409-B1 | Erythromycin derivatives, their process for preparation and their application as medicaments | AVENTIS PHARMA SA (FR) | 2003-03-19 | — | — | EP | disclosed |
| CN-1059445-C | Novel derivatives of erythromycin, their preparation and their use as medicaments | ROUSSEL UCLAF (FR) | 2000-12-13 | — | — | CN | disclosed |
| US-5760233-A | CHEMICAL INTERMEDIATES FOR MAKING ERYTHROMYCINS ANTIBIOTICS | ROUSSEL UCLAF (FR) | 1998-06-02 | — | — | US | disclosed |
| US-5656607-A | Erythromycin derivatives | ROUSSEL UCLAF (FR) | 1997-08-12 | — | — | US | disclosed |
| CN-1126997-A | Novel erythromycin derivatives, method for preparing same and use thereof as drugs | ROUSSEL UCLAF (FR) | 1996-07-17 | — | — | CN | disclosed |
| WO-1995027720-A1 | NOVEL ERYTHROMYCIN DERIVATIVES, METHOD FOR PREPARING SAME AND USE THEREOF AS DRUGS | ROUSSEL UCLAF (FR) | 1995-10-19 | — | — | WO | disclosed |
| EP-0676409-A1 | Erythromycin derivatives, their process for preparation and their application as medicaments | ROUSSEL UCLAF (FR) | 1995-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187720-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | ALDH1A1 209/4885KDM4E 1179/4885MAPT 2614/4885 |
| US-20260035358-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | CRBN, WEE1, WEE2 | ALDH1A1 3921/4885KDM4E 107/4885MAPT 643/4885 |
| US-20040097485-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | ALDH1A1 3037/4885KDM4E 4509/4885MAPT 3631/4885 |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | ALDH1A1 209/4885KDM4E 1179/4885MAPT 2614/4885 |
| US-20220396586-A1 | THIAZOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GOT2, ABAT, SDHA | ALDH1A1 416/4885KDM4E 2689/4885MAPT 1641/4885 |
| US-20250171438-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | ALDH1A1 865/4885KDM4E 104/4885MAPT 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.